Please wait a minute...
Journal of Neurorestoratology  2018, Vol. 6 Issue (1): 11-15    doi: 10.2147/JN.S148686
Expert Opinion     
Standards for the culture and quality control of umbilical cord mesenchymal stromal cells for neurorestorative clinical application (2017)
Qiang Ao1, Juan Xiao2,3, Yanqiu Yu4, Gengsheng Mao2, Qingyan Zou5, Wenyong Gao2,3, Hongyun Huang2,3
1Department of Tissue Engineering, China Medical University, Shen Yang
2Institute of Neurorestoratology, General Hospital of Armed Police Forces, Beijing
3Cell Therapy Center, Beijing Hongtianji Neuroscience Academy, Beijing
4Department of Pathophysiology, China Medical University, Shen Yang
5Guangdong 999 Brain Hospital, Guangzhou, People’s Republic of China
Download: PDF (125 KB)      HTML
Export: BibTeX | EndNote (RIS)      

Abstract  

Formulating common standards for the culture and quality control of umbilical cord mesenchymal stromal cells (MSCs) is crucial for the standardization of clinical neurorestorative therapy. But to date, there have been no standardized guidelines for the culture and quality control of MSCs in neurorestorative clinical application. Based on a relatively comprehensive review of published clinical studies as well as the existing methods of MSC culture and quality control, the Chinese Association of Neurorestoratology has developed standards for the culture and quality control of umbilical cord MSCs which possess the potential in neurorestorative clinical application. These guidelines include standardized training and management procedures for laboratory operators; standardized use and management of materials and equipment; standardized collection, culture and proliferation of umbilical cord MSCs; standardized management for cell preservation, transport and related safeguard measures; as well as standardization of a clean environment, routine maintenance and related tests and examinations and so on. These guidelines represent the minimum required standards for the culture and quality control of umbilical cord MSCs for potential use in current neurorestorative clinical therapy, and will be further optimized according to the progress of preclinical and clinical studies.



Key wordsstandardization      cell culture      quality control      mesenchymal stromal cells      clinical treatment      neurorestoratology      translational medicine     
Published: 26 June 2018
Corresponding Authors: Hongyun Huang   
About author:

*These authors contributed equally to this work

Cite this article:

Qiang Ao, Juan Xiao, Yanqiu Yu, Gengsheng Mao, Qingyan Zou, Wenyong Gao, Hongyun Huang. Standards for the culture and quality control of umbilical cord mesenchymal stromal cells for neurorestorative clinical application (2017). Journal of Neurorestoratology, 2018, 6: 11-15.

URL:

http://jnr.tsinghuajournals.com/10.2147/JN.S148686     OR     http://jnr.tsinghuajournals.com/Y2018/V6/I1/11

1.   Horwitz EM, Le Blanc K, Dominici M, et al; International Society for Cellular Therapy. Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy. 2005;7(5):393-395.
2.   Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317.
3.   Wang HS, Hung SC, Peng ST, et al. Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells. 2004;22(7):1330-1337.
4.   Galipeau J, Krampera M, Barrett J, et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016;18(2):151-159.
5.   Pansky A, Roitzheim B, Tobiasch E. Differentiation potential of adult human mesenchymal stem cells. Clin Lab. 2007;53(1-2):81-84.
6.   Wachsmuth L, S?der S, Fan Z, Finger F, Aigner T. Immunolocalization of matrix proteins in different human cartilage subtypes. Histol Histopathol. 2006;21(5):477-485.
7.   Chang YJ, Shih DT, Tseng CP, Hsieh TB, Lee DC, Hwang SM. Disparate mesenchyme-lineage tendencies in mesenchymal stem cells from human bone marrow and umbilical cord blood. Stem Cells. 2006;24(3):679-685.
8.   Tondreau T, Lagneaux L, Dejeneffe M, et al. Bone marrow-derived mesenchymal stem cells already express specific neural proteins before any differentiation. Differentiation. 2004;72(7):319-326.
9.   Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105(1):93-98.
10.   Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A. 2001;98(18):10344-10349.
11.   Krebsbach PH, Kuznetsov SA, Bianco P, Robey PG. Bone marrow stromal cells: characterization and clinical application. Crit Rev Oral BiolMed. 1999;10(2):165-181.
12.   Qiao C, Xu W, Zhu W, et al. Human mesenchymal stem cells isolated from the umbilical cord. Cell Biol Int. 2008;32(1):8-15.
13.   Tian Guo-Zhong, Yan Jun-Hao, Huang Hong-Yun, et al. Culture, purification and identification of human bone marrow stromal cells. J Anat. 2010,33(2):317-320.
14.   Chen SL, Fang WW, Ye F, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell inpatients with acute myocardial infarction. Am J Cardiol. 2004;94(1):92-95.
15.   Sanberg PR, Eve DJ, Willing AE, et al. The treatment of neurodegenerative disorders using umbilical cord blood and menstrual blood-derived stem cells. Cell Transplant. 2011;20(1):85-94.
16.   Richardson RM, Freed CR, Shimamoto SA, Starr PA. Pallidal neuronal discharge in Parkinson’s disease following intraputamenal fetal mesencephalic allograft. J Neurol Neurosurg Psychiatry. 2011;82(3):266-271.
17.   Liao GP, Harting MT, Hetz RA, et al. Autologous bone marrow mononuclear cells reduce therapeutic intensity for severe traumatic brain injury in children. Pediatr Crit Care Med. 2015;16(3):245-255.
18.   Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010;67(10):1187-1194.
19.   Attar A, Ayten M, Ozdemir M, et al. An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells. Cytotherapy. 2011;13(1):54-60.
20.   Tsolaki M, Zygouris S, Tsoutsikas V, Anestakis D, Koliakos G. Treatment with adipose stem cells in a patient with moderate Alzheimer’s disease: case report. J Neurorestoratology. 2015;3:115-120.
21.   Freedman MS, Bar-Or A, Atkins HL, et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler. 2010;16(4):503-510.
22.   Mehta T, Feroz A, Thakkar U, Vanikar A, Shah V, Trivedi H. Subarachnoid placement of stem cells in neurological disorders. Transplant Proc. 2008;40(4):1145-1147.
23.   Battistella V, de Freitas GR, da Fonseca LM, et al. Safety of autologous bone marrow mononuclear cell transplantation in patients with nonacute ischemic stroke. Regen Med. 2011;6(1):45-52.
24.   Friedrich MA, Martins MP, Araujo MD, et al. Intra-arterial infusion of autologous bone marrow mononuclear cells in patients with moderate to severe middle cerebral artery acute ischemic stroke. Cell Transplant. 2012;21():S13-S21.
25.   Ishige I, Nagamura-Inoue T, Honda MJ, et al. Comparison of mesenchymal stem cells derived from arterial, venous, and Wharton’s jelly explants of human umbilical cord. Int J Hematol. 2009;90(2):261-269.
26.   Ren Y, Tian G, Wang H, et al. Quality standard for olfactory ensheathing cells of human embryonic olfactory bulb. J Clini Rehabilitative Tissue Eng Res. 2008;12(16):3156-3157.
27.   Neurorestoratology Professional Committee of Chinese Medical Doctor Association. Guidelines for clinical application of neurorestoratology cell therapy of China (2015). Chin J Cell Stem Cell. 2016;6(1):1-7.
28.   Jiang X, Xiao J, Ren Y, et al. Effects of storage time at 4°C on viability of olfactory ensheathing cells derived from rat olfactory bulb. Prog Anat Sci. 2011;17(5):424-427.
[1] Hongyun Huang, Lin Chen, Gengsheng Mao, John Bach, Qun Xue, Fabin Han, Xiaoling Guo, Ali Otom, Elena Chernykh, Edgardo Alvarez, Andrey Bryukhovetskiy, Anna Sarnowaska, Xijing He, Milan Dimitrijevic, Ihsan Shanti, Klaus von Wild, Almudena Ramón-Cueto, Ziad Alzoubi, Gustavo Moviglia, Hamid Mobasheri, Adeeb Alzoubi, Wenchuan Zhang. The 2019 yearbook of Neurorestoratology[J]. Journal of Neurorestoratology, 2020, 8(1): 1-11.
[2] Xiaoling Guo, Xin Wang, Yan Li, Bo Zhou, Weidong Chen, Lihua Ren. Olfactory ensheathing cell transplantation improving cerebral infarction sequela: a case report and literature review[J]. Journal of Neurorestoratology, 2019, 7(2): 82-88.
[3] Lin Chen, Wise Young, Gustavo A. Moviglia, Ziad M. Al Zoubi. Summary report of the 11th Annual Conference of International Association of Neurorestoratology (IANR)[J]. Journal of Neurorestoratology, 2019, 7(1): 1-7.
[4] Hongyun Huang, Hari Shanker Sharma, Lin Chen, Hooshang Saberi, Gengsheng Mao. 2018 Yearbook of Neurorestoratology[J]. Journal of Neurorestoratology, 2019, 7(1): 8-17.
[5] Zikuan Leng, Nikhit Kethidi, Allen J. Chang, Lijun Sun, Jingjing Zhai, Yiting Yang, Jianzhong Xu, Xijing He. Muse cells and Neurorestoratology[J]. Journal of Neurorestoratology, 2019, 7(1): 18-25.
[6] Gengsheng Mao, Yunliang Wang, Xiaoling Guo, Jun Liu, Zuncheng Zheng, Lin Chen. Neurorestorative effect of olfactory ensheathing cells and Schwann cells by intranasal delivery for patients with ischemic stroke: design of a multicenter randomized double-blinded placebo-controlled clinical study[J]. Journal of Neurorestoratology, 2018, 6(1): 74-80.
[7] Zhongju Shi, Zhijian Wei, Shiqing Feng, Gustavo Moviglia, Lin Chen, Ping Wu. Highlights for the 10th Annual Conference of the International Association of Neurorestoratology[J]. Journal of Neurorestoratology, 2018, 6(1): 84-87.
[8] Shiqing Feng, Juan Xiao, Fabin Han, Lin Chen, Wenyong Gao, Gengsheng Mao, Hongyun Huang. Neurorestorative clinical application standards for the culture and quality control of neural progenitor/precursor cells (version 2017)[J]. Journal of Neurorestoratology, 2018, 6(1): 115-119.
[9] Hongyun Huang, Stephen Skaper, Gengsheng Mao, Hooshang Saberi, Shiqing Feng, Sang Ryong Jeon, Lin Chen, Milan Dimitrijevic. 2017 Yearbook of Neurorestoratology[J]. Journal of Neurorestoratology, 2018, 6(1): 67-73.
[10] Xiang Li, Guangsheng Li, Keith Dip-Kei Luk, Yong Hu. Neurorestoratology evidence in an animal model with cervical spondylotic myelopathy[J]. Journal of Neurorestoratology, 2017, 5(1): 21-29.
[11] Hongyun Huang, Gengsheng Mao, Shiqing Feng, Lin Chen. 2016 yearbook of neurorestoratology[J]. Journal of Neurorestoratology, 2017, 5(1): 111-115.
[12] Juan Xiao, Lin Chen, Gengsheng Mao, Wenyong Gao, Ming Lu, Xijing He, Hongyun Huang. Neurorestorative clinical application standards for the culture and quality control of olfactory ensheathing cells[J]. Journal of Neurorestoratology, 2017, 5(1): 175-179.
[13] Hongyun Huang, Lin Chen. Neurorestorative process, law, and mechanisms[J]. Journal of Neurorestoratology, 2015, 3(1): 23-30.
[14] Hongyun Huang, Gengsheng Mao, Lin Chen, Aibing Liu. Progress and challenges with clinical cell therapy in neurorestoratology[J]. Journal of Neurorestoratology, 2015, 3(1): 91-96.